Henry Ford Hospital Medical Journal
Volume 38

Number 4

Article 12

12-1990

An Overview of Renal Transplantation at Henry Ford Hospital
Warren L. Kupin
K. K. Venkat
Martin Mozes
Hajime Hayashi
Heung K. Oh

Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons

Recommended Citation
Kupin, Warren L.; Venkat, K. K.; Mozes, Martin; Hayashi, Hajime; and Oh, Heung K. (1990) "An Overview of
Renal Transplantation at Henry Ford Hospital," Henry Ford Hospital Medical Journal : Vol. 38 : No. 4 ,
241-245.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol38/iss4/12

This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has
been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health
System Scholarly Commons.

'-47.

i 1982,

AH

Overview of Renal Transplantation at Henry Ford Hospital

0/ rren L. Kupin, MD,* K. K. Veniiat, MD,* Martin Mozes, MD,
[iajinie Hayashi, PhD,* and Heung K. Oh, MD§

crease in the donor pool, the UNOS list will continue to increase
A sof January 1, 1990, approximately 106,000patients, disand the waiting period for a transplant will be similarly pro/ \ tributed among 1,830 dialysis centers nationwide, were relonged.
elving chronic hemodialysis or peritoneal dialysis for the treatWith this background of the iraportance of transplantation in
ment of end-stage renal disease (ESRD). A sirailar number of
the treatment of ESRD patients and the current probleras with
were
being
treated
in
Westem
Europe
and
the
Orient,
patients
supply and deraand of donor organs, we review the renal transbringing the total number of ESRD patients close to one-quarter
plant experience at Henry Ford Hospital (HFH) highlighting
of a million worldwide (I).
I) the role of HFH in providing transplantation in the state of
The acceptance rate for new patients into the ESRD prograra
Michigan, 2) patient and donor deraographics, 3) current irarauis highest in the United States at 150 per I million, followed by
nosuppressive therapy, and 4) graft and patient outcorae. EraJapan (137 per 1 million) and westem Germany (76 per I railphasis is placed priraarily on the results obtained since the introlion). The US dialysis popularion has been increasing at an anduction of cyclosporine A (CSA) imraunosuppressive therapy.
nual rate of 7% to 10% which currently necessitates a yearly
budget of $2.7 billion funded priraarily through the Medicare
ESRD prograra (2).
Transplantation at HFH
Although renal transplantation has been perforraed regularly
The renal transplant program at HFH was established in 1968
for renal replaceraent therapy since the raid 1960s, no specific
and is now one of eight transplant prograras in Michigan. As of
federal regulation of this procedure existed until the establishDeceraber 31, 1989, a total of 762 renal transplants have been
ment of the United Network for Organ Sharing (UNOS) in 1987.
perforraed in 697 parients at HFH. The distribution of these
This organization was created as a separate adrainistrative body
under the direction of the Health Care Finance Adrainistration
for overseeing the equitable distriburion of organ transplants
among the 218 transplant centers in the US. Seven organs corae
underthe auspices of this prograra: kidney, comea, heart, liver,
heart-lung, lung, and pancreas. One of the primary mandates of
the UNOS is the national sharing of phenotypic or 6 antigenmatched kidneys for cadaveric transplantation. This prograra
has increased the frequency of these transplants frora 1% in
1983-1987 to 8.1% of all cadaveric grafts in 1989 (3,4).
s
Asof June 1,1990,17,500 patients with ESRD werelisted on
the UNOS cadaveric renal transplant waiting list (5). The number of new potential transplant recipients entering this list has
been increasing by 6% per month which is in excess of the number of patients actually transplanted (approximately 4% per
TOonth). In the US, approximately 20% of all new patients entering the ESRD program are placed on the transplant waiting list.
Fig 1—Numberof patients receiving dialysis therapy in the US
Although this percentage is sirailar to that of other countries
(cross-hatched columns) and the number of renal transplants
(western Gerraany 20%, France 16%, and Belgiura 14%), selecperformed hy year (solid columns).
tion criteria for transplantarion have recently become less restrictive and this percentageraayincrease over the coraing years
Submitted for publication: April 6. 1990.
(5,6).
Accepted for publication: December 14, 1990,
Over the past five years the nuraber of cadaveric renal trans•Division of Nephrology and Hypertension, Henry Ford Hospital,
tDepartment of Surgery, Henry Ford Hospital,
plants perforraed in the US has remained relatively unchanged
^Department of Pathology, Henry Ford Hospital,
whereas the nuraber of patients entering the dialysis population
§Formerly Department of Surgery, Henry Ford Hospital. Currently Department of Trans'as steadily increased (Fig 1). Consequentiy, without an inplant Surgery, St. John Hospital, Detroit,
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Table 1
Comparison of the Number of Renal Transplants
Performed and the Number of Potential Recipients
on the Transplant Waiting List (1985 to 1990)
Patients on the Wailing Lisl*

Total Transplants

Year
1990
1989
1988
1987
1986
1985

Michigan
310
295
323
352
317

HFHt

Michigan

HFHt

673
710

81 (26%)
63 (21%)
52(16%)
51 (14%)
52(16%)

124(18%)
186 (26%)
173 (26%)
167(26%)
103(17%)
74(17%)

662

650
576
432

* As of January 1 st of each calendar year.
tPercentage of the total numberof transplants in Michigan performed at Henry Ford Hospital is shown by year.

Table 2
Distribution of Renal Transplants in Michigan
and Henry Ford Hospital (1985 to 1989)
Cadaveric Grafts
Year
1985
1986
1987
1988
1989

Michigan
266
290
256
236
232

Living-Related Grafts

HFH*

Michigan

HFH*

47(17.6%)
45 (15.5%)
42(16.4%)
48 (20.3%)
47 (20,2%)

51
62

5 (9.8%)
6 (9,6%)
10(14,9%)
15 (25,4%)
34 (43,5%)

67

59
78

•Percentage of thetotal number of tran.splants in Michigan performed at Henry Ford Hospital is shown by year.

transplants is as follows: 585 cadaveric (502 priraary and 83 repeat grafts), 173tiving-relateddonor (LRD) allografts, and four
Hving-unrelated donor (LURD) allografts. HFH accounted for
26% of all transplants performed in Michigan in 1989 (Table 1).
The distriburion of renal transplants at HFH over the past five
years is shown in Table 2. The increase in the number of transplants performed at HFH is primarily due to an increase in LRD
transplants rather than a change in the rate of cadaveric transplantation. This pattem has paralleled the national trend which
has shown miniraal change in the number of cadaveric grafts
transplanted over the past four years (Fig 1). Similar to the national trend, the dialysis population at HFH has been increasing by 10% per year and approximately 20% of the dialysis population is considered for transplantation.

Criteria for Transplantation
Contraindications for renal transplantation include: age > 70
years (a relative contraindication), active malignancy (a minimum of two years of complete remission in the case of a prior
malignancy), active serious infection, active chemical dependence, noncompliance withraedicaland/or dialysis therapy, advanced cardiovascular disease, positive huraan immunodefi-
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ciency virus (HIV) antibody, and positive hepatitis B surface
antigen carrier state. Noninsulin-dependent (type II) diabetes
raellitus was previously considered an absolute contraindication
for transplantation due to the high prevalence of underlying OQ.
cult cardiovascular disease. However, these patients can now be
candidates for transplantation if careful cardiac evaluation demonstrates no significant abnormalities.
Before a person can be accepted as a kidney donor, the foil
lowing criteriaraustbe raet: age < 60 to 65 years; established
brain death (for cadaveric donors); and absence of infection, extracranialraalignancy,impaired renal function, proteinuria, and
systeraic diseases such as diabetes mellitus and hypertension.
Donors must also have negative tests for HI V antibody and hepatitis B infection.
Since 1986, four LURD renal transplants have been performed at HFH. Such transplants are considered primarily as an
oprion between spouses. Aunts, uncles, cousins, and close personal friends with whom a long-standing personal bond exists
may also be considered in special circurastances. Evidence of
coercion or the possibility of monetary reimbursement for organ
donation are considered absolute contraindications.
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Demographics of Transplant
Recipients/Donors at HFH
The etiologies of ESRD among the patients receiving renal
transplants at HFH over the past five years are shown in Table 3,
This distribution is similar to the general representation of these
diseases araong the dialysis population. Theraajorityof transplanted diaberics have insulin-dependent (type 1) diabetes mellitus whereas type II diabetes predorainates among the dialysis
population. As menrioned previously, this is due to the older age
and extensive cardiovascular disease that excludes many type 11
diabetic patients from consideration for transplantation.
Overall, transplant patients are 59% white, 61 %raale,with an
average age of 45 ± 12 years for males and 38 ± 14 years for females. In coraparison, cadaveric transplant donors were 78%
white, 65%raale,with an average age at death of 27 + 10 years.
The majority of transplant recipients have been treated with
dialysis therapy prior to transplantation. Only 9% of all transplant recipients have never been on dialysis, whereas 70% w^^^
on heraodialysis and 21% on continuous ambulatory peritoneal
dialysis. The average duration of dialysis therapy was 2.1 ± ''^
years prior to transplantation.
The distriburion ofblood groups also parallels that seen in th'
general population as no specific renal disease has been associated with a particular blood group: blood group O: 46%, b'""
group B: 9%, blood group A: 36%, and blood group AB: 3%'
The waiting period for transplantation is approximately 2
for blood group O, 1.5 to 2 years for blood group B, and 0-5
1.0 year for blood group A. The paucity of blood group AB ^
cipients and the low frequency of this blood group in ge"^
raakes the waiting period unpredictable for these patients.
Another factor affecting the waiting period for cadave
grafts is the degree of sensirization of the parients. Pre^
blood transfusions, rejected allografts, and prior pregnancie io-
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the likelihood of the development of anti-human leuko''^^^^antibodies (HLA) that reduce the opportunity for transplan"-•y'^ and may have a deleterious effect on long-terra graft out1^"°" Currently 17% of HFH patients on the UNOS list are con'^vTred to be highly sensitized (> 80% pre-forraed lymphocytoantibodies against the HLA antigens prevalent in the gentoxic
tion). The waiting period for a graft for these patients
,al populai
gxceed seven years. The recent introduction of erythropoigreatiy reduced the need for regular blood transfusions
^'n'd may result in a reduction in the overall incidence of cyto""xic antibodies in the coming years.
' After harvesting, cadaveric allografts are routinely placed under cold preservation for storage periods of up to 48 hours prior
transplantation. The average duration of graft storage prior to
transplantation at HFH is 21 + 5 hours, which has reraained rel, jjvely unchanged over the past five years. The iraportance of
early graft placeraent after harvesting is supported by a direct
relationship between preservation time and posttransplant delayed graft function (DGF). As national data suggest slightly
worse one-year graft survival in patients with DGF, early graft
implantation is desirable. The incidence of DGF at HFH in primary cadaveric kidney transplant recipients is approximately
25%.
Among LRD transplants, parents accounted for 18% of donors, siblings 78%, and offspring 4%. Perfectiy matched sibling
pairs (2-haplotyperaatch)coraprise approxiraately 31 % of LRD
transplants.

Immunosuppression Protocols
The imraunosuppression regimen employed in the HFH kidney transplant prograra between 1968 and Noveraber 1983 involved corabined therapy with azathioprine (AZA) and corticosteroids (CS). In the mid 1970s the protocol was expanded to
include a two-week prophylactic intravenous infusion of a polyclonal antilymphocyte preparation (antithyraocyte globulin
[ATO] or Minnesota antilyraphoblast globulin [MALG]) iraraediately after transplantation (for cadaveric transplant recipients
only), followed byraaintenancetherapy with AZA and CS (referred to as conventional immunosuppression).
CSA, first utilized at HFH in December 1983, is now the primary maintenance iraraunosuppressive agent for both cadaveric
and LRD renal transplantation. Current protocols continue to include prophylactic adrainistration of MALG or a raonoclonal
antilyraphocyte antibody preparation (0KT3) for grafts without
immediate function due to preservation injury. The purpose of
these protocols is to avoid the potential for concomitant CSAtelated renal damage superimposed upon the preservation-induced acute tubular necrosis which is responsible for DGF.
Because of the significant long-term coraplications of CS
therapy (diabetes, hypertension, weight gain, infection, hyper'ipidemia, cataracts, aseptic necrosis), a raajor goal in our program is coraplete withdrawal of CS in both priraary cadaveric
LRD renal transplant recipients, withraaintenancetherapy
'Consisting of corabination CSA and AZA. Approxiraately 65%
'0 70% of patients have been successfully withdrawn frora CS
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Table 3
Etiology of End-Stage Renal Disease Among Transplant
Recipients at Henry Ford Hospital (1985 to 1989)
Condition

1985

1986

1987

1988

1989

Diabetes mellitus
Hypertension
Chronic glomerulonephritis
Polycystic kidney disease
Alport's syndrome
Heroin nephropathy
Chronic pyelonephritis
Miscellaneous

25%
17%
25%
17%
3%
0%
3%
10%

25%
18%
18%
20%
0%
7%

18%
21%
13%
16%
5%
5%
3%
19%

13%
42%
18%
9%
4%
0%
11%
3%

21%
33%
19%
14%
5%
0'/,.
5%
3%

O'/f

12%

CSA
CONV.

' p < 0.05, CSA va. Conventional therapy

Months Posttransplant

Fig 2—Actuarial five-year survival of primary cadaveric transplants performed utilizing either CSA or conventional immunosuppression at Henry Ford Ho.spital.

six to 12 months posttransplant with a marked improveraent in
many of the CS-related side effects.
Because the long-term nephrotoxicity of CSA has been of
concem, the CSA dose is adjusted downward during the first
threeraonthsposttransplant to achieve specifically defined target trough levels. As a result, renal function as deterrained by
the semm creatinine is not significantly different in CSA-treated
cadaveric (1.7 mg/dL) and LRD (1.4 mg/dL) recipients, compared to conventionally treated cadaveric (1.5 mg/dL) and LRD
(1.2 mg/dL) recipients in our prograra.
CSA-related malignancy has occurred in four cases: one case
each of primary B-cell lymphoraa ofthe sraall bowel and central
nervous system lymphoraa, and two cases of renal cell carcinoma in the native kidneys. All four patients died as a result of
their malignancy.

Graft and Patient Survival
Graft survival has improved significantly in our program
since the addition of CSA as maintenance therapy corapared to
conventional iramunosuppression for cadaveric transplantation
(Fig 2). One- and five-year primary cadaveric graft survival
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Table 4
Actuarial Graft Survival for Living-Related
and Repeat Cadaveric Renal Transplants
in Cyclosporine-Treated Patients

Table 5
Duration of Hospitalization (days) for
Renal Transplant Recipients
Type of Transplant

1 Year
2 Years
3 Years
4 Years
5 Years

Living-Related Grafts

Repeal Cadaveric Grafts

95%
93%
89%
79%
79%

37%
27%
23%
23%
23%

Year

Primary Cadaveric

Repeat Cadaveric

1989
1988
1987
1986
1985

15±13
17± 15
21 ± 15
20 ±15
19+13

19±7
18±5
17±4
I8±6
I9±6

Living-Related
10 ± 3
9±3
9±3
I6± 10
11 ± 7

itigates again:
ee of HLA ra
Clearly, the g
improvement ir
decreasing the
(,f patient morti
ataft rejection
ptessive therap
^ould benefit t

We wish to
Kijewski, RN,

rates are 75% and 60%, respectively, for CSA-treated patients
versus 61% and 43%, respectively, for conventionally treated
recipients. The half-life of a primary cadaveric graft (defined as
thetimeposttransplant where graft survival is 50%) is 7.7 years
for CSA-treated patients and 4.4 years for conventionally treated
patients.
Importantly, the primary advantage of CSA appears to be attained within the first year posttransplant; after the first year the
rate of graft loss is similar in the two groups. This finding demonstrates that graft loss after the first year posttransplant raay
not be specifically related to imraunosuppressive therapy and
that the degree of HLA-raisraatching between donor and recipient and other noniramunologic mechanisras may be contributing to graft loss.
Patient survival has also been significantly iraproved during
the CSA era (one-year survival: 90.5% CSA versus 84% conventionally treated, P < 0.05;five-yearsurvival: 78% CSA versus 71% conventionally treated, P < 0.05). Theraajorcause of
death in both groups was infection (45%) followed by cardiovascular disease (32%). Malignancy accounted for 4.5% of patient deaths.
Actuarial graft survival of CSA-treated LRD transplant recipients is 95% at one year and 79% at five years posttransplant
(Table 4). Parient survival was 95% at one year and five years
posttransplant.
Patients receiving a repeat renal transplant do not appear to
have benefited frora the institution of CSA therapy, and the
overall success rate is significantly lower corapared to priraary
cadaveric grafts (Table 4). The majority of these grafts are lost
within the first three months either from priraary nonfunction,
which is felt to be an immunologically mediated event, or from
acute cellular rejection.

Duration of Hospitalization
A continued decrease in the length of initial hospital stay for
primary cadaveric renal transplant recipients has been noted
over the past three years (Table 5) which resulted from a change
tn the duration of prophylactic polyclonal orraonoclonalanti-
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body adrainistration. Shorter courses of initial therapy as well as
the ability to continue any anti-rejection therapy on an outpa.
tient basis with 0KT3 have led to a current hospital stay of lm
13 days for priraary cadaveric recipients (30% decrease since
1987). The duration of hospitalization for repeat graft and LRD
transplant recipients has reraained unchanged over the past five
years.

Conclusions
Renal transplantation is now considered to be the best option
for renal replaceraent therapy in patients with ESRD and is associated with significantly improved graft and patient survival, especially since the introducfion of CSA asraaintenanceimmunosuppression in 1983. HFH has played araajorrole in providing
renal transplantation in Michigan for the past 20 years, yet the
future growth of not only this prograra but transplantation ona
national scale is irapeded by a critical shortage of donors in contrast to the rapidly growing nuraber of patients on the transplant
waiting list. This shortageraustbe overcorae to avoid prolonged
and unacceptable delays in obtaining grafts which at present already exceed one year for most patients. The extra burden on
these patients who thenraustbe teraporarily supported in dialysis faciliriesraakesit important that this problem be resolved expedientiy.
Recent public opinion polls have demonstrated that > 95% of
the public is aware of organ donation but only 50% were acWally willing to donate their own organs (63% said they woula
donate the organs of a relative) and only 15% to 20% have actually signed their donor cards. Local attempts to improve the donor pool by increasing physician and public awareness of organ
donation have been initiated at HFH with the development
the Life-Share Program. On the state level a similar effort has
been enacted through the forraation of the Transplant Advocate
Group.
Results of repeat transplants are currently unacceptably
and consequentiy theraajorityof patients awaiting repeat gra"*
have been listed with the UNOS only for perfectiy matched graft*'
Although the waiting period may be extremely prolonged W
this stipulation, the current poor success rate in these patic"'*
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f-ord He

• tes against continued transplantation without a high de•"'fof HLA matching.
""^Clearly- the goals for the 1990s should include: 1) continued
vement in transplant iraraunosuppression, particulariy in
'"^^'^'asing the incidence of infection which is the raajor cause
atient mortality; 2) investigation into the causes of chronic
^ft rejection which appear to be independent of iraraunosupsive therapy; and 3) increasing the organ donor pool which
'"ould benefit both renal and extra-renal organ transplantation.
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